IHC
An AI-based test developed by South Korean biotech Lunit may improve identification of best responders to immunotherapy when used alongside PD-L1 testing.
FDA Approves Merck's Keytruda for MSI-H, dMMR Endometrial Cancer With Roche CDx
The agency approved the checkpoint inhibitor for this new indication based on response data from the multi-arm KEYNOTE-158 basket trial.
Carsgen to Start Phase II Trial of CAR T-Cell Therapy for Advanced Gastric, GEJ Cancer in China
The firm will evaluate the autologous cell therapy CT041 for patients with previously treated, CLDN18.2-positive advanced gastric and gastroesophageal cancer.
Multiomic Profiling Uncovers Predictors of Melanoma Response to Immunotherapy
A model based on the results could predict treatment response but was less able to forecast resistance, suggesting heterogeneous mechanisms.
Zymeworks, ALX Oncology Dose First HER2-Expressing Cancer Patient in Targeted Combo Trial
The companies are evaluating Zymeworks' bispecific antibody zanidatamab plus ALX's CD47-targeting agent evorpacept for HER2-expressing breast and other cancers.